Hanna Wielińska-Wiśniewska

Hanna Wielińska-Wiśniewska

Auto-generated profile, based on publicly available information

Hanna Wielińska-Wiśniewska

Department of Pediatric Gastroenterology and Metabolic Diseases, Poznan University of Medical Sciences, Szpitalna Str. 27/33, 60-572 Poznań, Poland

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2021 in Journal of Medical Science
Verified
Journal Article
Open access
Małgorzata JamkaMałgorzata Jamka
Małgorzata Jamka
AMAleksandra Makarewicz
Aleksandra Makarewicz
MWMaria Wasiewicz-Gajdzis
Maria Wasiewicz-Gajdzis
Jan BrylakJan Brylak
Jan Brylak
HWHanna Wielińska-Wiśniewska
Hanna Wielińska-Wiśniewska
JWJarosław Walkowiak
Jarosław Walkowiak
This study aims to assess the effect of an increase in daily physical activity to prevent cognitive decline, sustain brain volumes and maintain healthy biomarker levels in previously inactive (< 7,000 steps/day) mild cognitive impairment (MCI) subjects aged 50-65 years. In total, 198 subjects with MCI (assessed using the Montreal Cognitive Assessment test) will be recruited and randomised into two groups: active and passive. The active group will be instructed, encouraged and motivated to increase their physical activity to a moderate level (≥ 10,000 steps/day), while the passive group should maintain their normal activity levels. All subjects will undergo cognitive assessment, neuroimaging and biomarker tests before and after a one-year intervention. During the intervention, physical activity will be measured by the Fitbit Inspire HR wristband. The study was registered in the German Clinical Trials Register database (registration no. DRKS00020943, date of registration: 09.03.2020, protocol version: 1.0).

11 April 2025 in Healthcare
Verified
Journal Article
Open access
PDF file
Małgorzata JamkaMałgorzata Jamka
Małgorzata Jamka
AMAleksandra Makarewicz
Aleksandra Makarewicz
JPJoanna Popek
Joanna Popek
PKPatrycja Krzyżanowska-Jankowska
Patrycja Krzyżanowska-Jankowska
HWHanna Wielińska-Wiśniewska
Hanna Wielińska-Wiśniewska
JWJarosław Walkowiak
Jarosław Walkowiak
Background: Previous studies suggested that decreased saliva lactoferrin (LF) levels might be used to differentiate subjects with mild cognitive impairment (MCI) from subjects with normal cognitive function (NCF). Here, we aimed to assess differences in plasma LF concentrations between subjects with NCF and MCI. Methods: In total, 113 NCF subjects and 113 MCI individuals were included in this study. Cognitive function was assessed using the Montreal Cognitive Assessment (MoCA) scale, and anthropometric parameters, body composition, physical activity, cardio-metabolic parameters, and LF levels were measured. Results: MCI subjects had significantly lower LF levels than NCF participants (p < 0.0001). There were also significant differences between the study groups in the smoking history (p = 0.0190), alcohol consumption (p = 0.0036), intake of hypoglycaemic drugs (p = 0.0140), vigorous activity (MET-min/day: p = 0.0223, min/day: p = 0.0133), and energy expenditure associated with activity (p = 0.0287). Moreover, the MoCA test results significantly correlated with LF levels (p = 0.0026), and there were significant differences between MoCA tertiles and LF levels (p = 0.0189). Also, adjusted logistic regression analysis results showed that LF concentrations (p = 0.0382), alcohol consumption (p = 0.0203), and intake of hypoglycaemic drugs (p = 0.0455) were independent predictors of MCI prevalence. Conclusions: In conclusion, MCI subjects are characterised by lower plasma LF concentrations than NCF individuals, but further studies are needed to confirm these findings.